Oxford Biodynamics Share Discussion Threads

[pj84] 23/7/2024 19:48

"tevevubes" I presume is "the revenues" and "1w" months of cash is presumably "12" months.

I agree just over 12 months of cash if nothing happens and I expect we have about 6 months or so before the issue of funds starts to become an issue again.

The trades over the past week or so seem to suggest selling but the price movement suggests there is buying or a buy being filled.

[bones698] 22/7/2024 17:37

Not good news then. Cash burn here has always been high and raising funds in this market is painful and that's the concern here. The share price has fallen and wil continue to while they keep needing cash and tevevubes are not high enough to offset the losses. Unfortunately these type of sales are slow to grow and get to that level and so more funding needed.

They have about 1w months of cash to deliver something good now. What that may be remains to be seen. Keeping an eye on it though

[pj84] 22/7/2024 10:23

Doesn't look like it was successful so probably won't be any RNS to confirm.

[pj84] 17/7/2024 21:18

It looks like the MRC meeting dates might have been on 3 and 4 July.



If so, 10 working days from 4 July would be 18 July and if successful OBD should be notified tomorrow with possibly an RNS tomorrow or the day after.

[pj84] 11/7/2024 20:23

At the risk of tempting fate, the decision by the MRC should be known at any time within the next 3 weeks and in the above link it states "Projects must start on 1 August" so I am not expecting a decision to go to the wire on 31 July.

Good luck all holders.

[pj84] 25/6/2024 18:07

From the timeline it looks like the interviews are tomorrow or the day after and I haven't seen any news of anyone else being shortlisted (happy to be corrected if wrong).

"Timeline

Opening date 25 January 2024 9:00am

Closing date 9 May 2024 4:00pm

Interview 26 or 27 June 2024

Funding decision meeting July 2024

Informed of funding decision: within 10 working days of funding decision meeting"

[pj84] 25/6/2024 09:48

Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy.

[pj84] 24/6/2024 19:24

It's probably best if I say yes, so you can focus on your other 2 threads.

[npk2] 24/6/2024 18:49

So you have asked and I stand by original statement.I hope that's clarification enough for you.

[pj84] 22/6/2024 23:33

That's your interpretation and equally on a free thread I can genuinely question your motives, not having seen you post here or anywhere else before.

[npk2] 22/6/2024 20:39

I'll remember to ask your permission to post my thoughts on a free thread before I post next time.I wasn't aware that you were the monitor for discussion on OBD.

[pj84] 22/6/2024 00:00

Obviously it's a free bet and the worst that can happen for the CEO is that the bet lapses without ever being exercised.

But with 10m share options it clearly incentives the CEO. If he doubles the share price from the fund raise to 18p he stands to benefit by nearly £1m.

Not sure why you have chosen OBD to share your wisdom on, as as far as I can see, the last 10 pages (could be more) of your posting history seems to be solely on the "Flat Earth" thread and the "New World order" thread, neither of which appear to be investment threads? But each to there own.

[npk2] 21/6/2024 23:17

A free bet until it wins. Only then do you need to place your wager.I'd suggest that on both past and current performance, Snr Mgt should worry more about their current employment before any further fleecing of the company payroll.

[pj84] 21/6/2024 20:58

Good to see that the CEO's 10m share options are tied in to the performance of the shares relative to the recent fund raise, as he only benefits if the share price exceeds 9p, and the more the share price exceeds 9p the more he and those who invested in the fund raise stand to gain. Looking more like a partnership deal would benefit all shareholders as well as the CEO.

[bones698] 19/6/2024 12:01

Agree not a viable business and will need a lot more money to get anywhere near and a few years away. Whilst it looks cheap I can see this as a 1p share soon

[yellowstoneadvisory] 19/6/2024 08:10

If you missed the OBD webinar yesterday you can catch up here.

[pj84] 18/6/2024 22:56

There are significant risks and so far I have taken a small position in OBD, particularly as the potential for the PSE test is huge.

There is no guarantee the rate of increase in tests will grow as quickly as I hope, but I hope it does and that could lead to an increase in share price and the potential for raising at a higher price and I will be interested to see the update in early October.

However, if you listened to the webinar update today you will have heard that for both the PSE and CiRT tests OBD isn't stubbornly going to try and avoid partnerships with big companies with deep pockets and big distribution networks and they are prepared to explore partnerships that could have an upfront payment, with milestone payments and royalties and the CEO said that a lower upfront payment tied to milestone payments to tie in with the interests of a partner would be attractive looking at the growing royalties on the market penetration a big partner could open up. I hope that is what they manage to do.

[elpirata] 18/6/2024 12:10

This just doesnt stack as a future viable business, 53 staff in situ paid £2.978m gross ie an average annualised salary of £112,000 & £6m pa in total (R&D is extra!), plus annualised normal admin costs excluding exceptionals £4.4m ie £10m+

12,000 pse target @ £750 ie £9m sales @ 40% margin taken from those accounts ie £3.6m gross profit before admin costs. Add CiRT fwiw.

This can only end with a bigger biotech picking up the IP & shareholders shafted

[bones698] 18/6/2024 11:25

They will need. Alot more funding to get anywhere near and that's the problem. Revenues are hardly taking off here and it will be years and a lot more dilution before they get there. The losses are ridiculous for a company delivering so little in revenue. Poorly managed and will shaft pis again and again

[pj84] 18/6/2024 11:08

This is now all about scale up and execution.

For EpiSwitch PSE “Our PSE vertical is led by SVP Business and Corporate Development, Dr Steven Arrivo whose appointment we announced in November 2023. Steve and the rest of the team are targeted with growing sales of PSE to 1,000 per month.” At 12,000 tests pa that is 26 times increase, on the 454 tests sold since launch.

Thesa are targets and it is now about how quickly they can approach those targets.

“We will provide an update on tests ordered to the end of the financial year shortly after 30 September 2024.”

Can’t immediately see any targets for the EpiSwitch CiRT tests but the aim will be to scale these up as well.

The update in October should give an early indication of how the scale up is progressing.

[2nell] 18/6/2024 08:29

Oh dear hope the muppets have all sold!!

[bones698] 15/6/2024 12:12

Next fund raise must be not far away and that's likely to see this at 1-2p hence it continues to fall even with various news releases trying to prop it up so they cna get it away at a better price. Sadly that's failed miserably and expect to see this get hammered when it's announced like so mnay others

[bones698] 12/6/2024 20:35

Unfortubtaley cash and the long times for any meaningingful data and contracts mean this will need a lot more cash and get dilluted heavily.

[pj84] 06/6/2024 09:33

That could be a very significant trial as although it is a 5 year trial they will be taking samples every 3 months and there is a very good chance of some very good data long before the final outcome.

[minja19] 06/6/2024 07:46

RNS today....